Ardelyx, Inc.
ARDX Real Time Price USDRecent trades of ARDX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ARDX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$620,000 Apr 18, 2025 Issue: Health Issues
-
$670,000 Jan 17, 2025 Issue: Health Issues Medicare/Medicaid
-
$720,000 Oct 16, 2024 Issue: Health Issues
-
$530,000 Jul 10, 2024 Issue: Health Issues
-
$530,000 Apr 02, 2024 Issue: Health Issues
-
$60,000 Jan 22, 2024 Issue: Health Issues
-
$60,000 Jan 22, 2024 Issue: Health Issues
-
$80,000 Jan 21, 2024 Issue: Medicare/Medicaid
-
$60,000 Jan 20, 2024 Issue: Medicare/Medicaid Health Issues
-
$460,000 Oct 06, 2023 Issue: Medicare/Medicaid
-
$310,000 Jul 17, 2023 Issue: Medicare/Medicaid
-
$130,000 Jan 17, 2023 Issue: None
-
$50,000 Oct 20, 2022 Issue: Health Issues
-
$30,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$130,000 Jul 22, 2022 Issue: None
-
$130,000 Apr 20, 2022 Issue: None
-
$260,000 Jan 20, 2022 Issue: None
-
$240,000 Oct 20, 2021 Issue: None
-
$220,000 Jul 19, 2021 Issue: None
-
$190,000 Apr 19, 2021 Issue: None
-
$170,000 Jan 21, 2021 Issue: None
-
$30,000 Oct 20, 2020 Issue: Medicare/Medicaid
-
$30,000 Jul 20, 2020 Issue: Medicare/Medicaid
-
$30,000 Apr 21, 2020 Issue: Medicare/Medicaid
-
$30,000 Jan 21, 2020 Issue: Medicare/Medicaid
-
$30,000 Oct 18, 2019 Issue: Medicare/Medicaid
-
$30,000 Jul 12, 2019 Issue: Medicare/Medicaid
-
$30,000 Apr 04, 2019 Issue: Medicare/Medicaid
-
$10,000 Jan 09, 2019 Issue: Medicare/Medicaid Health Issues
Estimated quarterly lobbying spending
ARDX Revenue by Segment or Geography
New patents grants
-
Patent Title: Hormone receptor modulators for treating metabolic conditions and disorders Jan. 28, 2025
-
Patent Title: Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists Sep. 10, 2024
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Jun. 25, 2024
-
Patent Title: Glycyrrhetinic acid derivatives for use in treating hyperkalemia Jan. 02, 2024
-
Patent Title: Compounds and methods for inhibiting phosphate transport Nov. 14, 2023
-
Patent Title: Glycyrrhetinic acid derivatives for treating hyperkalemia Sep. 26, 2023
-
Patent Title: Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders Sep. 12, 2023
-
Patent Title: Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators Aug. 08, 2023
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders May. 03, 2022
-
Patent Title: Compounds useful for treating gastrointestinal tract disorders Feb. 08, 2022
-
Patent Title: Inhibitors of nhe-mediated antiport Oct. 19, 2021
-
Patent Title: Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators Aug. 17, 2021
-
Patent Title: Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists Apr. 06, 2021
-
Patent Title: Nhe3-binding compounds and methods for inhibiting phosphate transport Mar. 09, 2021
-
Patent Title: Hormone receptor modulators for treating metabolic conditions and disorders Oct. 06, 2020
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Jan. 28, 2020
-
Patent Title: Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists Aug. 27, 2019
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Aug. 20, 2019
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Aug. 13, 2019
-
Patent Title: Nhe3-binding compounds and methods for inhibiting phosphate transport Apr. 30, 2019
-
Patent Title: Compositions and methods for treating hyperkalemia Mar. 20, 2018
-
Patent Title: Compositions and methods for treating hyperkalemia Jan. 16, 2018
-
Patent Title: Compositions and methods for treating hyperkalemia May. 23, 2017
-
Patent Title: Pharmaceutical compositions for treating hyperkalemia Jan. 24, 2017
-
Patent Title: Pharmaceutical compositions for treating hyperkalemia Jan. 17, 2017
-
Patent Title: Compositions and methods for treating hyperkalemia Sep. 06, 2016
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder Aug. 09, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Apr. 05, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 22, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 22, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 08, 2016
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Apr. 14, 2015
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Mar. 03, 2015
-
Patent Title: Compounds and methods for inhibiting phosphate transport Dec. 23, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 26, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 26, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 19, 2014
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Sep. 24, 2013
Federal grants, loans, and purchases
- $12,100 2024-10-01 00:00:00 Agency: Department of Veterans Affairs
- $6,049 2024-05-23 00:00:00 Agency: Department of Veterans Affairs
- $0 2024-04-29 00:00:00 Agency: Department of Veterans Affairs
- $6,049 2024-04-15 00:00:00 Agency: Department of Veterans Affairs
- $6,049 2024-04-15 00:00:00 Agency: Department of Veterans Affairs
- $0 2022-03-25 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded from public contracts
Recent insights relating to ARDX
Recent picks made for ARDX stock on CNBC
ETFs with the largest estimated holdings in ARDX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ARDX stock a Buy, Sell, or Hold?
- What is the price target for $ARDX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ARDX stock?
- Who owns the most shares of $ARDX stock?
- What funds own $ARDX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ARDX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.